Plastic and Reconstructive Surgery, Global Open (Apr 2019)

Synchronous Breast Implant–associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications

  • Rita A. Mukhtar, MD,
  • Michael Holland, MD,
  • David A. Sieber, MD,
  • Kwun Wah Wen, MD, PhD,
  • Hope S. Rugo, MD,
  • Marshall E. Kadin, MD,
  • Gregory R. Bean, MD, PhD

DOI
https://doi.org/10.1097/GOX.0000000000002188
Journal volume & issue
Vol. 7, no. 4
p. e2188

Abstract

Read online

SUMMARY:. A 59-year-old woman with a history of cosmetic implants developed ipsilateral synchronous breast implant–associated anaplastic large cell lymphoma (BIA-ALCL) and invasive ductal carcinoma in the left breast. Each tumor was subjected to next-generation sequencing, and separate analyses revealed mutually exclusive aberrations: an activating STAT3 mutation in the lymphoma and a PIK3CA in-frame deletion in the carcinoma. The patient was treated with removal of implants, capsulectomy, partial mastectomy, sentinel node biopsy, radiotherapy, and endocrine therapy with no evidence of recurrence for 1 year. This case illustrates the importance of obtaining thorough evaluation for concomitant malignancies in the breast at the time of diagnosis of BIA-ALCL. Herein, we review the current recommendations for evaluation and management of BIA-ALCL.